Head-to-head · WeighScore
AM Rx vs Royal Medical Center
The verdict
AM Rx takes it — 49.9/100 to 49.4/100, but only just.
AM Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. AM Rx (getamrx.com) is a telehealth platform operated by FitRX, LLC (also operates Zealthy and FitRx). Royal Medical Center is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | AM Rx | Royal Medical Center |
|---|---|---|
| WeighScore | 49.9/100 | 49.4/100 |
| Grade | C | C |
| Scorecard rank | #490 | #492 |
| Semaglutide | $151/mo (quarterly plan, plus a separate fee, compounded) | Not disclosed |
| Tirzepatide | Not disclosed | $450/mo (2.5 mg dose, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #490 · C
Strengths
- Insurance coordination for brand-name GLP-1s — as low as $25/mo
- All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
- HSA and FSA accepted
- Video visits available with providers averaging 10+ years' experience
- Compounded semaglutide from $151/mo on the quarterly plan
Where it loses points
- Active FTC/DOJ lawsuit over deceptive billing and subscription practices
- Novo Nordisk false-advertising lawsuit (Aug 2025)
- Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
- Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #492 · C
Strengths
- Physician founder Dr. Dagoberto Rodriguez, MD — Emory residency, former Coral Springs Medical Center chairman, U Miami faculty
- Tirzepatide pricing fully itemized by dose tier ($450 / $650 / $800 / $1,100) — more transparent than 'starting at' floors
- All-inclusive pricing bundles medication, supplies, injections, lab monitoring, and physician follow-ups
- Broad catalog (HRT, TRT, peptides, ED, hair, vitamins) reflects an established multi-program clinic
- Florida physician with 30+ years of practice — a strong physician-led care signal
Where it loses points
- Operating legal entity not disclosed — only the 'Royal Medical Center' brand surfaced
- Pharmacy partner not named — buyers can't verify licensure or 503A/503B status
- No LegitScript badge displayed
- States served not enumerated — site says 'nationwide' with no state list
- Headline 'starting at $116/mo' conflicts with the actual $450/mo tirzepatide floor
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.